沙库巴曲缬沙坦辅助治疗对冠心病心力衰竭患者血清hs-CRP、NT-proBNP水平的影响

Effects of Adjuvant Treatment with Sacubitril/Valsartan on Serum hs-CRP and NT-proBNP Levels in Elderly Patients with Coronary Heart Disease and Heart Failure

目的:探讨沙库巴曲缬沙坦辅助治疗对冠状动脉粥样硬化性心脏病(CHD)心力衰竭(简称心衰)患者血清超敏C-反应蛋白(hs-CRP)、氨基末端脑钠肽前体(NT-proBNP)水平的影响。方法:选取2019年1月至2021年1月上饶市立医院收治的CHD心衰患者60例作为此次的研究对象,随机分为观察组和对照组各30例。对照组予以美托洛尔治疗,观察组在此基础上予以沙库巴曲缬沙坦治疗。连续治疗2个月后,对比患者疗效;对比治疗前后患者心功能及血清指标变化;记录治疗期间患者出现的不良反应。结果:连续治疗2个月后,观察组患者治疗有效率高于对照组(P<0.05);治疗后两组患者舒张早期最大充盈速度(E峰)、左心室射血分数(LVEF)及E/A较治疗前均有提升,且观察组高于对照组(P<0.05),两组患者舒张晚期最大充盈速度(A峰)较治疗前均有下降,且观察组低于对照组(P<0.05);治疗后两组患者血清hs-CRP、NT-proBNP水平较治疗前均有降低,且观察组低于对照组(P<0.05);治疗过程中两组患者均未出现严重不良反应(P>0.05)。结论:沙库巴曲缬沙坦辅助治疗CHD心衰患者能有效提升治疗效果,改善患者心功能,降低血清hs-CRP、NT-proBNP水平,缓解修复心肌损伤,降低机体炎症水平,安全性较高。

Objective:To explore the effects of adjuvant treatment with sacubitril/valsartan on levels of serum high-sensitivity C-reactive protein(hs-CRP)and N-terminal pro-brain natriuretic peptide(NT-proBNP)in patients with coronary heart disease(CHD)and heart failure.Methods:A total of 60 patients with CHD and heart failure admitted to Shangrao Municipalhospital were enrolled as the research objects between January 2019 and January 2021.They were randomly divided into observation group and control group,30 cases in each group.The control group was treated with metoprolol,while observation group was additionally treated with sacubitril/valsartan.After 2 months of continuous treatment,curative effect,and changes in cardiac function and serum indexes before and after treatment were compared between the two groups.The adverse reactions during treatment were recorded.Results:After 2 months of continuous treatment,the response rate of treatment in observation group was higher than that in control group(P<0.05).After treatment,maximum early diastolic filling velocity(E),left ventricular ejection fraction(LVEF)and E/A in both groups were improved,which were higher in observation group than control group(P<0.05).After treatment,maximum filling velocity in late diastole(A)in both groups was decreased,which was lower in observation group than control group(P<0.05).After treatment,levels of serum hs-CRP and NT-proBNP in both groups were decreased,which were lower in observation group than control group(P<0.05).During treatment,there were no serious adverse reactions in either group(P>0.05).Conclusion:The adjuvant treatment with with sacubitril/valsartan can effectively improve the curative effect and cardiac function in patients with CHD and heart failure,reduce levels of serum hs-CRP and NT-proBNP,alleviate and repair myocardial damage,and reduce inflammation level,with relatively higher safety.